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Abstract
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
bright light therapy effective in treating depression in adults with seasonal affective disorder?”
STUDY DESIGN: A systematic EBM review of two randomized controlled trials and one
randomized crossover trial published between the years 2011 and 2015, all in English language.
DATA SOURCES: All three studies were published in peer-reviewed journals found using
PubMed and selected based on relevance to the clinical question and evaluating POEMS.
OUTCOMES MEASURED: The outcomes measured were reduction in depressive symptoms
and severity using the Structured Interview Guide for the Hamilton Depression Rating Scale and
the Beck Depression Inventory Scale II.
RESULTS: Reeves et al. found that there was a statistically significant difference in reduction of
depressive complaints in individuals with SAD exposed to bright light therapy compared to those
exposed to dim red light with a p-value of 0.02 (J Nerv Ment Dis. 2012;200(1):51-5). Rohan et
al. found that in individuals with SAD, depression severity and remission improved when
exposed to light therapy, however no significant difference was seen between these individuals
and those exposed to CBT, with a p-value of 0.30 for depression remission and a p-value of 0.13
for depression severity (Am J Psychiatry. 2015;172(9):862-869.
doi:10.1176/appi.ajp.2015.14101293). Meester et al. found that in individuals with SAD,
depressive complaints decreased when exposed to standard bright light therapy, however no
significant difference was seen between these individuals and those exposed to low intensity blue
light, with a p-value of >0.05 (BMC Psychiatry. 2011;11:17. Published 2011 Jan 28.
doi:10.1186/1471-244X-11-17).
CONCLUSION: The results of all three trials show that bright light therapy is a promising
method for treating depression in adults with seasonal affective disorder, however further
research is required to assess whether it is any more effective than other methods currently being
used.
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INTRODUCTION
Seasonal affective disorder (SAD) is defined as a condition where individuals undergo
recurrent major depressive episodes based on a characteristic seasonal pattern. SAD most
commonly affects individuals during the fall and winter months, with remission during the spring
and summer seasons. Common symptoms someone suffering from SAD will present with are very
similar to those seen in major depressive disorder, including changes in appetite, sleep
disturbances, fatigue and decrease in energy, as well as decreased activity or enjoyment in things
that usually bring pleasure.1
Seasonal affective disorder affects between 1-10% of the population and is four times more
likely to occur in women compared to men.2 The prevalence of this disorder in North America
increases with latitude, with a higher rate of seasonal affective disorder occurring in Alaska (9%)
compared to Florida (1%).3 The exact number of healthcare visits for SAD is unknown, however
in 2016, the CDC reported that the percent of physician office visits with depression indicated on
the medical record was 9.3%.4 It is hard to estimate how many people seek treatment for SAD, as
research has found that half of the time, depression is not detected during healthcare visits, even if
the patient is feeling depressed.5 Likewise, the direct total healthcare cost for SAD has also not
been identified. However, a study conducted in 2015 from Greenburg and colleagues estimated
that $210.5 billion is spent each year on major depressive disorder, of which SAD is a subset.6
While the exact cause of SAD has not yet been identified, it is thought that
neurotransmitters, hormones, genetics, dysfunction of the circadian rhythm and psychosocial
factors all play a role.7 Specifically, serotonin levels are thought to play a major part in the
development of SAD, as winter months show the lowest rate of serotonin turnover in the human
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brain and serotonin is thought to be responsible for helping with mood balance.7 As sunlight starts
to diminish during the fall, there is a corresponding decrease in serotonin activity, and therefore a
dysregulation in balancing mood.3 A 2014 study by McMahon et al. found that in individuals
affected by SAD, there were higher levels of SERT, “a protein that assists with transportation of
serotonin from the synaptic cleft to the presynaptic neuron.”8 The higher the SERT levels, the
lower the serotonin activity, and the greater the likelihood of developing depression.
While there is no cure for SAD, there are multiple different treatment options that have
been proven to play a role in improving depressive symptoms in affected individuals. One of the
most commonly used methods to treat this condition is conventional medication therapy through
the use of antidepressant drugs, specifically selective serotonin reuptake inhibitors (SSRIs) and
bupropion. Psychotherapy, such as cognitive behavioral therapy and interpersonal psychotherapy,
has also been seen to be effective in helping to treat these patients. Other treatment options include
electroconvulsive therapy and negative air ionization.9
Previous studies have shown bright light therapy to be effective in treating symptoms of
SAD due to the fact that light has an effect on serotonin levels and circadian rhythm, both of which
are thought to play a role in the pathophysiology of this disorder.7 Results of a 2010 study
published in the Journal of Psychiatric Practice showed that bright light therapy was effective in
not only improving depressive symptoms in individuals with SAD, but also helped with depression
remission in these patients.10
Since depression and SAD are becoming more prevalent and the healthcare cost continues
to rise, it is essential for healthcare providers to not only be looking out for patients presenting
with depressive symptoms, but also important that providers are knowledgeable about different
treatment options available, especially those that may be more cost-effective and possibly show
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better results. While it was demonstrated in the previously mentioned 2010 study that light therapy
can be an effective treatment method for SAD, updated data is necessary to further support this
claim. This systematic review evaluates two randomized controlled trials (RCTs) and one
randomized crossover study comparing the efficacy of bright light therapy as an appropriate
treatment for depression in adults with SAD to other light therapies or psychotherapy treatments.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is bright light
therapy effective in treating depression in adults with seasonal affective disorder?”.
METHODS
Research for each study was done via PubMed using the key words “seasonal affective
disorder” and “light treatment.” All articles selected were published in English in peer-reviewed
journals. Articles were selected based on relevance to my clinical question and if the outcomes of
the studies were patient oriented (POEMS). Inclusion criteria included studies published in the last
10 years, involving humans, and based on clinical trials studying individuals with a current
diagnosis of major depression with a seasonal pattern. Articles were excluded if they were
published before 2008 and not based off of clinical trials.
The studies selected for this EBM review included 2 RCTs and one randomized crossover
trial comparing bright light therapy to other treatment options as well as placebos. The population
studied included adults with seasonal affective disorder. All three studies used bright light therapy
as the experimental intervention. Comparison groups were treated with low intensity blue light,
dim red placebo light, or cognitive behavioral therapy-SAD (CBT-SAD). The outcomes measured
in each study were the overall improvement of depressive symptoms and severity in patients with
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SAD, assessed by participant answers to depression questionnaires. The statistics used in the
articles include RBI, ABI, NNT, confidence interval, and p-value.
Table 1. Demographics and Characteristics of Included Studies
Study
Reeves1
(2012)

Type
Randomized
Crossover
Study

#Pts
79

Age (yrs)
18-65

Inclusion Criteria
Individuals 18-65
years old with a dx
of current major
depressive
disorder with
seasonal specifier

Rohan11
(2015)

RCT

177

>18

Meester12
(2011)

RCT

23

Standard
light:
39.9 +/12.7

Individuals >18
years old, who met
DSM-IV-TR
criteria for
recurrent major
depression, with a
seasonal pattern,
fulfilled SIGHSAD criteria for a
current SAD
episode, and not
using or stable use
of antidepressants
Patients meeting
the criteria for a
major depressive
disorder, seasonal
pattern, winter
type according to
the DSM-IV-TR

Blueenriched
light:
41.7 +/13.1

Exclusion Criteria
Patients with a
psychotic disorder,
current suicidality,
vision problems not
correctable by
glasses, light
sensitivity,
overnight workers,
illicit drug or
alcohol abuse in last
year, and any
antidepressant or
antipsychotic
medication use in
last 30 days
Patients who have
ever used light
therapy or
psychotherapy for
depression, have a
comorbid axis I
disorder requiring
treatment, suicidal
intent,
hypothyroidism, or
would be absent for
more than a week in
March
Not reported

W/D
0

Interventions
1 hour of bright
white light at
10,050 lux and a
peak wavelength
of 545nm VS
dim red placebo
light at 42 lux
with a peak
wavelength of
612nm

14

10,000 lux
bright light
therapy, starting
at 30 minutes
and reaching a
maximum of 2
hours per day
over 6 weeks VS
two 90-minute
sessions per
week of CBT for
6 weeks

1

10 days of
standard light at
10,000 lux for
30 minutes a day
VS 10 days of
blue-enriched
light at 750 lux
for 30 minutes a
day

OUTCOMES MEASURED
The studies measured depressive symptoms and severity of patients both pre and post
treatment using patient-reported depression scales. Reeves et al. used the Beck Depression
Inventory Second Edition (BDI-II) to measure the severity of depressive symptoms of individuals
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participating in the study.1 The BDI-II is a 21-item self-reported measure of a patient’s depressive
symptom severity. Individuals rank items on a scale of 0-3 based on how they have been feeling
for the last 2 weeks.1 The sum of these numbers equates to the participant’s BDI-II score. Reeves
et al. administered the BDI-II 3 times in one day (at baseline, after light session one, and after light
session two), each time instructing participants “to report on the past two weeks, including today.”1
Rohan et al. also used the BDI-II for outcome measurements, which was administered pretreatment, mid-treatment (week 3), and post-treatment (week 6).11 Meester et al. measured
depressive symptom severity with the Structured Interview Guide for the Hamilton Depression
Rating Scale- Seasonal Affective Disorder (SIGH-SAD), which is a 24-item self-rated depression
scale that was administered at baseline, at day 8 (after 5th light session), at day 15 (after 10th light
session), and at day 22 (1 week after light treatment had ended).12
RESULTS
Two RCTs and one randomized crossover trial were conducted to determine if bright light
therapy is effective for treating depression in adults with SAD. All three studies included
participants over the age of 18 who met the criteria for major depressive disorder with a seasonal
pattern. Demographics of participants are included in Table 1.
The Reeves et al. study was a randomized crossover design comparing bright light therapy
to dim red placebo light. There were 79 participants included in the study, with 41 being exposed
to the experimental bright light first and 38 being exposed to the placebo light first.1 Before
treatment, the severity of each participants depression was assessed using the BDI-II. Individuals
in the experimental group were exposed to 1 hour of bright white light at 10,050 lux and a peak
wavelength of 545 nm, while those in the placebo group were exposed to dim red light at 42 lux
and a peak wavelength of 612nm.1 After the first hour, the BDI-II was re-administered, then
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participants switched groups. After the second hour, the depression scale was administered again.
At the end of the study, zero participants dropped out and everyone was accounted for.1 Details of
compliance were otherwise not discussed in the article. A mixed-model crossover analysis was
conducted to control for “within-subject correlation and assess whether the light effect differed by
order of light exposure. This was accomplished by including an interaction of light group by order
of light administration.”1 The interaction was removed if it was found to be insignificant. A pvalue of </= 0.05 was used to determine statistically significant differences between treatment
groups. A borderline interaction effect was determined, but was not statistically significant
(p=0.07).1 When this effect was removed from the model and the light effects were grouped
together over the 2 hours, bright light showed to have a significantly greater effect on reducing
depressive symptoms compared to dim red light after the second period, with a p-value of 0.02, as
shown in Table 2.1
Table 2. Results of Reeves et al. Study Comparing Bright and Red Light Therapy
Baseline
First Period
Second Period
Mean (SE)
Mean (SE)
p
Mean (SE)
BDI Bright light first: 23.1 (9.0) Bright light: -2.78
0.54 Bright light:-2.40
Red light first: 26.2 (11.0)
(0.80)
(1.05)
Red light: -2.08 (0.82)
Red light: 0.34 (0.46)

p
0.02

The Rohan et al. study was a RCT with 2 arms comparing individuals with SAD treated
with bright light therapy (BLT) versus cognitive behavioral therapy-SAD (CBT-SAD) for 6 weeks,
starting the first week of February.11 The intent-to-treat sample consisted of 177 patients randomly
assigned to either the BLT or CBT group. In the light therapy group, 89 individuals were exposed
to bright light set at 10,000 lux.11 Individuals started out being exposed to 30 minutes of light as
soon as they woke up. The daily dose of light was increased by 15 minutes each week, reaching a
maximum of 2 hours/day, over the course of 6 weeks.11 Two participants were unable to tolerate
the minimum dose of 30 minutes of light therapy, so they ended treatment at 15-minutes of
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morning-only light sessions daily.11 After 6 weeks, participants were encouraged to continue light
therapy until May, however were not monitored. In the CBT group, 88 individuals were exposed
to two 90-minute sessions per week of CBT-SAD for 6 weeks. CBT-SAD uses traditional
cognitive behavioral therapy and adapts it to target SAD and improve individual’s abilities to cope
with winter darkness and changes in weather.11 The BDI-II was administered to participants before
treatment, mid-treatment, and after treatment. One participant withdrew from the light therapy
group and thirteen participants withdrew from the CBT-SAD group. Seven of the thirteen who
withdrew from the CBT-SAD group did not attend any sessions, while the other six attended
anywhere from 2-7 sessions. Only 22 participants in the CBT-SAD group attended all 12
sessions.11 No further discussion of compliance was mentioned. The conductors of the study were
able to obtain data from the 1 individual who withdrew from the BLT group and from 9 individuals
who withdrew from the CBT-SAD group.11
A Pearson’s chi-square test and a 95% confidence interval (CI) were used to compare the
difference in depressive symptom ratings between treatment groups as well as the number of
individuals in remission after each treatment. As seen in table 3, the mean change in depressive
symptoms from baseline was 16.2 for the BLT group and 14.5 for the CBT-SAD group.11 A
significant reduction in depressive symptoms was seen over the course of the study in participants
in both treatment groups (p<0.001), however, no significant difference was seen between groups
(p=0.13). The 95% CI for the 1.0-point difference between groups post-treatment was -1.3-3.3.11
Table 3. Comparison of Bright Light Therapy and CBT-SAD Effectiveness on Reducing SAD
Depressive Symptoms Measured by the BDI-II, conducted by Rohan et al.
Group
Mean BDI-II Score (SE) Mean Change from
p-value
95% CI
Baseline (SE)
Light Therapy
Pre-treatment: 23.4 (8.4) 16.2
Main effect of time:
Post-treatment: 7.2 (6.0)
<0.001
-1.3-3.3
Main effect of
CBT-SAD
Pre-treatment: 22.7 (9.3) 14.5
treatment: 0.13
Post-treatment: 8.2 (6.7)
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In terms of depression remission, a participant was considered in remission if their BDI-II
score was </=8 post-treatment.11 Table 4 shows that 63.6% of individuals in the light therapy
group achieved remission, while 56.0% of individuals in the CBT-SAD group achieved
remission. The difference in depression remission between groups was determined to be
insignificant, with a p-value of 0.30 and a 95% CI of -22.5-7.1.11
Table 4. Comparison of Bright Light Therapy and CBT-SAD Effectiveness on Achieving
Depression Remission Measured by the BDI-II, conducted by Rohan et al.
Group
Posttreatment Remission p-value
95% CI for Difference
Between Treatments
Light Therapy
63.6%
0.30
-22.5-7.1
CBT-SAD
56.0%
The data from the study was used to calculate the number needed to treat (NNT) for
depression remission which was 14, as shown in table 5. This indicates that for every 14 people
treated with BLT, one more person will have remission of SAD compared to if they had been
treated with CBT-SAD.
Table 5. Statistical Analysis of Rohan et al. Study on the Efficacy of BLT in Achieving
Depression Remission in Individuals with SAD
NNT
RBI
ABI
14
-0.136
-0.076
The Meester et al. study was a randomized control trial with 2 arms including an
experimental group exposed to standard bright light therapy (SLT) and a control group exposed to
blue-enriched light therapy (BELT) at a lower intensity.12 The sample included 23 participants,
however after a few days of light treatment, 1 person dropped out, leaving 22 participants. In the
experimental group, 3 men and 8 women were treated with SLT at 10,000 lux for 30 minutes a
day for 10 days over the course of 2 weeks, with weekends excluded.12 In the control group, 2 men
and 9 women were treated with BELT at 750 lux for 30 minutes a day for the same number of
days.12 Individuals in each group started day 1 with a baseline measurement of depression severity
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using the SIGH-SAD. The SIGH-SAD was then administered again after the 5th light session, after
the 10th light session, and 1 week after treatment had ended. A responder to treatment was defined
as a participant whose depressive symptoms improved by at least 50%.12 No details regarding
compliance were discussed throughout the literature.
As seen in table 6, by day 22, individuals in the SLT group had, on average, a 16.7 point
reduction in their SIGH-SAD depression score, while those in the BELT group had an average
reduction of 19.4 points.12 A two-tailed alpha level of 0.05 was used to determine statistical
significance between treatment groups. While results showed a statistically significant decrease in
depressive symptoms in participants from both the SLT and BELT groups (p<0.001), there was
no significant difference seen between groups (p>0.05).12
Table 6. Comparison of Standard Light Therapy and Blue-Enriched Light Therapy Based on
Average Depression Scores Measured by the SIGH-SAD, conducted by Meester et al
Condition
N
Day 1
Day 22 (SD) Change from Responder N
p-value
(SD)
Baseline
SLT
11
25.6 (6.3) 8.9 (6.8)
16.7
8
Main effect of
time: <0.001
BELT
11
25.4 (6.9) 6 (4.0)
19.4
11
Main effect of
condition: >0.05
The data from the study was used to calculate the NNT which was -3, as shown in table
7. This indicates that for every 3 people treated with SLT, one fewer will have remission of SAD
compared to if they were treated with BELT.
Table 7. Statistical Analysis of Meester et al. Study on the Efficacy of SLT in Improving
Depressive Symptoms of SAD
NNT
RBI
ABI
-3
.273
.273
DISCUSSION
The studies discussed in this systematic review suggest that bright light therapy is
effective in treating depression in adults with seasonal affective disorder. All 3 studies found the
decrease in depressive complaints from pre and post treatment of individuals exposed to bright
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light therapy to be statistically significant with p-values <0.05.1,11,12 However, 2 out of the 3
studies found that while bright light therapy was effective in reducing depressive symptoms, it
was no more effective than other forms of treatment for SAD, including CBT-SAD, as
demonstrated by Rohan et al. or blue-enriched light of lower intensity as demonstrated by
Meester et al.11,12
All three studies had their limitations as well. Reeves et al. used a crossover study design
to conduct their research which may have lead to carryover effects of each treatment.1 Also, there
was a significant difference in baseline POMS-D scores for the participants in each group, with a
p-value of 0.04.1 While this was not the outcome of interest studied in this systematic review, it is
a depression scale, indicating a significant difference in depressive symptoms between groups at
the start of the study. Recruitment methodology may have also affected outcomes as individuals
were recruited from advertisements in newspapers rather than from clinical treatment programs,
resulting in a sampling error.1
The limitation of the Rohan et al. study was that they used a single site to conduct their
CBT-SAD therapy, with only one principal investigator employed to review the audiotaped
sessions.11 Using a more diverse group of sites where participants could chose to attend their CBTSAD sessions may have helped with result accuracy and eliminating bias. Also, the sample size
was limited in racial diversity, with the majority of the participants being Caucasian.11
Meester et al. used a small sample size (n=22) to conduct their study which could have
affected the results.12 Also, no placebo condition was included in this study due to the difficulty in
creating a “real placebo condition for visible light treatment.”12 This means that the similarities in
depression score responses between both treatments groups could be seen as a “placebo effects
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only.”12 Additionally, no exclusion criteria were listed for this study. Other factors such as family
problems and comorbid conditions, which play a major role in depression were not accounted for.
In terms of limitations of this EBM review, the lack of double-blind randomized controlled
trials conducted assessing the efficacy of bright light therapy as a treatment for SAD could have
led to biased research. Length of treatment also differed significantly between studies, putting
limitations on the results presented. Follow-up of patients was insufficiently long for both the
Reeves et al. study (2 hours) and the Meester et al. study (22 days).1,12 Side effects from bright
light therapy including headaches, insomnia, and light sensitivity are also factors that should be
taken into account when considering this as a treatment option for SAD patients. Access to
treatment and insurance coverage were not issues presented in any of the literature chosen for this
review.
CONCLUSION
Based on the articles reviewed for this systematic EBM paper, bright light therapy is
effective in treating depression in individuals with SAD. All three studies discussed above showed
a statistically significant decrease in depressive complaints of individuals with SAD who were
treated with bright light therapy. That being said, these studies show that it may not be more
effective than low-intensity light or other treatment options currently available for treating SAD.
Bright light therapy may be a good cost-effective alternative for individuals who do not want to
take medication for depression or are unable to attend therapy sessions. However, due to the
limitations of these studies, future research is needed to further investigate the efficacy of bright
light therapy as a main treatment option for individuals with SAD. In order to help strengthen
results, future studies can aim to include larger sample sizes, sufficiently long treatment and
follow-up times, and conduct studies in a double-blind fashion.
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